LONG R3IGF-I is an analogue of IGF-I engineered for biopharmaceutical protein production in mammalian cells, supporting growth and survival in serum-free media at concentrations at least 200-fold lower than insulin.
preclinical — animal, cell or mechanistic work — not yet about people
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
LONG R3IGF-I is an analogue of IGF-I engineered for biopharmaceutical protein production in mammalian cells, supporting growth and survival in serum-free media at concentrations at least 200-fold lower than insulin. · pmid:17172665
Mechanism
It has markedly reduced binding to IGF-binding proteins; in rats it circulated mostly as free peptide and was cleared from plasma faster than IGF-I. · pmid:7693845
Identity
No public registry record is shown for this page: PubChem gave no record that proves it is this substance.
Where the evidence actually sits
Preclinical only100%
Proportion of the 2 claims about IGF-1 LR3 standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for IGF-1 LR3 yet.
Dose evidence, rung by rung
No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
nothing resolved on this rung
Observational evidence· resolved human data at the emerging tier: thin, or contested
nothing resolved on this rung
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
LONG R3IGF-I as a more potent alternative to insulin in serum-free culture of HEK293 cells. · pmid 17172665 · 2006
Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I) and an analogue LR3IGF-I in pregnant rats. · pmid 7693845 · 1993
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.